Scholarlink

<p>Photodynamic therapy (PDT) is a minimally invasive cancer treatment that employs photosensitizers (PSs) activated by light to generate cytotoxic reactive oxygen species (ROS). Talaporfin sodium (TS), widely used in Japan, has shown limited efficacy in advanced tumors, highlighting the need for novel PSs. We developed a glucose-conjugated bacteriochlorin derivative, Glc-TFPB, designed to enhance tumor selectivity via the Warburg effect and to enable deep tissue penetration owing to its near-infrared absorption. In vitro, Glc-TFPB exhibited time-dependent cellular uptake, predominantly in lysosomes, and induced significant ROS generation and apoptosis upon PDT. Compared with TS, Glc-TFPB-PDT demonstrated markedly higher cytotoxicity 24&#xa0;h after administration (IC50: 1.10&#xa0;µM vs 13.60&#xa0;µM). In vivo fluorescence analysis revealed peak tumor accumulation at 24&#xa0;h after administration, consistent with optimal treatment timing. PDT with Glc-TFPB significantly suppressed tumor growth in xenografted mice, with greater efficacy at 24&#xa0;h than at 2&#xa0;h after administration. These findings indicate that Glc-TFPB is a promising next-generation PS with improved tumor selectivity, deeper tissue penetration, and superior photodynamic efficacy, supporting its potential for clinical translation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Antitumor effects of a novel glucose-conjugated bacteriochlorin for photodynamic therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月25日

查看全文
  • Yasunari Sasaki,
  • Mamoru Tanaka,
  • Yuki Kojima,
  • Makiko Sasaki,
  • Tomohiro Watada,
  • Ryusei Yamasaki,
  • Kanato Matsuura,
  • Akihiro Nomoto,
  • Shigenobu Yano,
  • Tomokazu Yoshimura,
  • Atsushi Narumi,
  • Keiji Ozeki,
  • Takaya Shimura,
  • Eiji Kubota,
  • Hiromi Kataoka

摘要

Photodynamic therapy (PDT) is a minimally invasive cancer treatment that employs photosensitizers (PSs) activated by light to generate cytotoxic reactive oxygen species (ROS). Talaporfin sodium (TS), widely used in Japan, has shown limited efficacy in advanced tumors, highlighting the need for novel PSs. We developed a glucose-conjugated bacteriochlorin derivative, Glc-TFPB, designed to enhance tumor selectivity via the Warburg effect and to enable deep tissue penetration owing to its near-infrared absorption. In vitro, Glc-TFPB exhibited time-dependent cellular uptake, predominantly in lysosomes, and induced significant ROS generation and apoptosis upon PDT. Compared with TS, Glc-TFPB-PDT demonstrated markedly higher cytotoxicity 24 h after administration (IC50: 1.10 µM vs 13.60 µM). In vivo fluorescence analysis revealed peak tumor accumulation at 24 h after administration, consistent with optimal treatment timing. PDT with Glc-TFPB significantly suppressed tumor growth in xenografted mice, with greater efficacy at 24 h than at 2 h after administration. These findings indicate that Glc-TFPB is a promising next-generation PS with improved tumor selectivity, deeper tissue penetration, and superior photodynamic efficacy, supporting its potential for clinical translation.